CHF136.00
0.37% today
SIX Swiss Exchange, Aug 22, 10:47 am CET
ISIN
CH1335392721
Symbol
GALD
Index

Galderma Target price 2025 - Analyst rating & recommendation

Galderma Classifications & Recommendation:

Buy
79%
Hold
21%

Galderma Price Target

Target Price CHF140.76
Price CHF136.50
Potential
Number of Estimates 15
15 Analysts have issued a price target Galderma 2026 . The average Galderma target price is CHF140.76. This is higher than the current stock price. The highest price target is
CHF173.25 26.92%
register free of charge
, the lowest is
CHF113.12 17.13%
register free of charge
.
A rating was issued by 19 analysts: 15 Analysts recommend Galderma to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2026 of . Most analysts recommend the Galderma stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion CHF 3.59 4.13
7.86% 14.93%
EBITDA Margin 21.80% 22.34%
1.50% 2.47%

17 Analysts have issued a sales forecast Galderma 2025 . The average Galderma sales estimate is

CHF4.1b
Unlock
. This is
8.81% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF4.4b 15.16%
Unlock
, the lowest is
CHF3.9b 1.96%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF3.6b 7.86%
2025
CHF4.1b 14.93%
Unlock
2026
CHF4.8b 16.03%
Unlock
2027
CHF5.5b 15.52%
Unlock

12 Analysts have issued an Galderma EBITDA forecast 2025. The average Galderma EBITDA estimate is

CHF922m
Unlock
. This is
7.14% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF977m 13.53%
Unlock
, the lowest is
CHF872m 1.32%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF783m 9.48%
2025
CHF922m 17.77%
Unlock
2026
CHF1.2b 27.19%
Unlock
2027
CHF1.5b 24.21%
Unlock

EBITDA Margin

2024 21.80% 1.50%
2025
22.34% 2.47%
Unlock
2026
24.49% 9.62%
Unlock
2027
26.33% 7.51%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 0.79 2.23
515.79% 182.28%
P/E 61.11

13 Analysts have issued a Galderma forecast for earnings per share. The average Galderma EPS is

CHF2.23
Unlock
. This is
74.22% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF2.43 89.84%
Unlock
, the lowest is
CHF2.04 59.38%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF0.79 515.79%
2025
CHF2.23 182.28%
Unlock
2026
CHF3.19 43.05%
Unlock
2027
CHF4.22 32.29%
Unlock

P/E ratio

Current 106.64 106.95%
2025
61.11 42.70%
Unlock
2026
42.78 30.00%
Unlock
2027
32.38 24.31%
Unlock

Current Galderma Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JEFFERIES
Locked
Locked
Locked Jul 17 2025
BERENBERG
Locked
Locked
Locked Jul 01 2025
BERENBERG
Locked
Locked
Locked Mar 31 2025
JEFFERIES
Locked
Locked
Locked Mar 27 2025
BERENBERG
Locked
Locked
Locked Nov 25 2024
BNP PARIBAS EXANE
Locked
Locked
Locked Aug 21 2024
Analyst Rating Date
Locked
JEFFERIES:
Locked
Locked
Jul 17 2025
Locked
BERENBERG:
Locked
Locked
Jul 01 2025
Locked
BERENBERG:
Locked
Locked
Mar 31 2025
Locked
JEFFERIES:
Locked
Locked
Mar 27 2025
Locked
BERENBERG:
Locked
Locked
Nov 25 2024
Locked
BNP PARIBAS EXANE:
Locked
Locked
Aug 21 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today